Tigecycline 50MG Injection

Tigecycline 50 mg Injection
Broad-Spectrum Strength for Today’s Toughest Infections

Tigecycline 50 mg Injection is a next-generation glycylcycline antibiotic engineered to combat a wide range of multidrug-resistant (MDR) organisms. With broad-spectrum activity, including MRSA, VRE, and ESBL-producing bacteria, Tigecycline is an essential tool for treating complex infections in hospitalized patients.

Broad-Spectrum Efficacy – Active against gram-positive, gram-negative, anaerobic, and atypical pathogens
Effective Against Resistant Strains – Covers MRSA, VRE, ESBLs, and Acinetobacter baumannii
Versatile Clinical Use – Approved for complicated intra-abdominal infections (cIAI), complicated skin & soft tissue infections (cSSTI), and community-acquired pneumonia (CAP)
Hospital-Grade Antibiotic – Trusted in critical care and infectious disease settings for difficult-to-treat infections

Indications:

• Complicated intra-abdominal infections (cIAI)

• Complicated skin and skin structure infections (cSSTI)

• Community-acquired bacterial pneumonia (CAP)

Important Safety Information:
Not recommended in pediatric patients under 8 years or for bloodstream infections. Use with caution in patients with hepatic impairment. Monitor for potential nausea, vomiting, and liver function abnormalities.